Maxim’s Jason Kolbert sheds light ahead of tomorrow’s Phase 1 oral endoxifen findings.
Analyst sees a bright future on the horizon.
Atossa Genetics may have taken a beating in the market yesterday after investors ran for the hills with fears of share dilution running …
Shares of breast cancer detection device maker Atossa Genetics Inc (NASDAQ:ATOS) are tumbling nearly 23%, as of this writing. The reason?
Shares of Atossa Genetics Inc (NASDAQ:ATOS) tumbled 43% in morning trade Thursday, after the healthcare company’s stock offering priced at a deep discount. The …
‘Sell the News’ Action Is Taking Atossa Genetics Shares Down Today, Atossa Genetics Inc (NASDAQ:ATOS) investors are scratching their heads as to why …
Today, Atossa Genetics Inc (NASDAQ:ATOS) investors are scratching their heads as to why the stock collapsed following the news that the company’s breast …
Atossa Genetics Inc (NASDAQ:ATOS) announced the pricing of an underwritten public offering of 1,150,000 shares of its common stock at a price to …
Chicago IL / Research Report Wire / February 27th, 2015 / Institutional Analyst Inc.(IA) announced today it released the its Top 20 Biotech …